Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Merck and its rivals make tens of billions of dollars a year from the mechanism and are ... regardless of PD-L1 expression. Junshi, Coherus' PD-1 inhibitor Loqtorzi scores in phase 3 liver cancer ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

BeiGene’s trials suggest that this mechanism, combined with chemotherapy, offers survival benefits in PD-L1-expressing cancers. Tevimbra is part of a competitive PD-1 inhibitor market ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

More information: Ignacio Melero et al, Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours, Nature (2024). DOI: 10.1038/s41586-024-08305-z ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...